Midiana (Drospirenone, Ethinylestradiol)

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while ethinylestradiol supplies estrogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, lowering LH and FSH, which prevents ovulation. The progestin also thickens cervical mucus and alters the endometrium, creating conditions that inhibit sperm penetration and implantation.

The dosage regimen for Midiana is set by the prescribing healthcare professional. Typically the product is taken once daily at the same time each day, but the exact strength, tablet count and duration are determined by the prescriber based on individual patient needs.

Midiana is contraindicated in pregnancy and should be discontinued if pregnancy is confirmed. Use during breastfeeding is generally not recommended unless the benefits outweigh the risks; clinicians should discuss individual circumstances with the patient and consider alternative contraception if needed.

To order Midiana, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Midiana offers efficacy comparable to other combined oral contraceptives. Its drospirenone component provides anti‑mineralocorticoid activity, which may result in a lower risk of water retention and a different side‑effect profile compared with products containing other progestins. Safety, tolerability and individual patient factors guide the choice of one COC over another.

Midiana tablets should be stored at room temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct heat, and keep out of reach of children. Do not use the product after the expiry date printed on the packaging.

Midiana is taken orally as a tablet once daily, preferably at the same time each day. It may be taken with or without food. Consistent daily intake helps maintain effective hormone levels for reliable contraception.

The most serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial thrombosis (stroke, myocardial infarction), severe hypertension, and rare liver tumors such as hepatocellular adenoma. Patients should seek immediate medical attention if they experience unexplained leg pain, chest pain, severe headache, visual changes, or abdominal pain.

Midiana should not be used by women who are pregnant, have a history of thromboembolic disease, uncontrolled hypertension, certain liver disorders, known hypersensitivity to drospirenone, ethinylestradiol or any excipients, or who are smokers over the age of 35. A thorough medical assessment is required before initiating therapy.